MONTREAL, QUEBEC -- (MARKET WIRE) -- 06/14/2006 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, presented today a scientific poster reporting on the high genetic barrier and favorable cross-resistance profile of its lead HIV protease inhibitor (PI) PPL-100 at the 15th International HIV Drug Resistance Workshop, in Sitges, Spain.
